Your browser doesn't support javascript.
loading
Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States.
Sussell, Jesse; Singh Jhuti, Gurleen; Antao, Vincent; Herrera-Restrepo, Oscar; Wehler, Elizabeth; Bilir, S Pinar.
Affiliation
  • Sussell J; Genentech Inc., South San Francisco.
  • Singh Jhuti G; Genentech Inc., South San Francisco.
  • Antao V; Genentech Inc., South San Francisco.
  • Herrera-Restrepo O; US HEOR and Real World Evidence Solutions, IQVIA, Falls Church, VA.
  • Wehler E; US HEOR and Real World Evidence Solutions, IQVIA, Plymouth Meeting, PA.
  • Bilir SP; US HEOR and Real World Evidence Solutions, IQVIA, San Francisco, CA.
Am J Clin Oncol ; 44(7): 340-349, 2021 07 01.
Article in En | MEDLINE | ID: mdl-34151896
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Chemotherapy, Adjuvant / Ado-Trastuzumab Emtansine Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Female / Humans Country/Region as subject: America do norte Language: En Journal: Am J Clin Oncol Year: 2021 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Chemotherapy, Adjuvant / Ado-Trastuzumab Emtansine Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Female / Humans Country/Region as subject: America do norte Language: En Journal: Am J Clin Oncol Year: 2021 Document type: Article Country of publication: